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 4 
Introduction 
The United States is an increasingly medicated society. Nearly 70% of Americans report 
prescription medication use in the past year (Zhong et al., 2013), with more than 4.3 billion 
prescriptions dispensed in 2015 alone (IMS Institute for Healthcare Informatics, 2016). Recent 
trends in prescription drug development, direct-to-consumer advertising, and expansions in 
health insurance and prescription drug coverage have fueled dramatic increases in prescribing 
(National Center for Health Statistics, 2016). As a result, since the early 1990s, the proportion of 
Americans reporting prescription medication use during the past 30 days has increased by more 
than ten percentage points among young and middle-aged adults (National Center for Health 
Statistics [NCHS], 2016), with even greater increases among older Americans (NCHS, 2016; 
Qato, Wilder, Schumm, Gillet, & Alexander, 2016). Between 2013 and 2015, prescription drug 
spending in the United States grew by nearly 20%, totaling more than $425 billion in 2015 (IMS 
Institute for Healthcare Informatics, 2016). Spending is predicted to increase by an additional 
46%, to more than $620 billion, within the next three years (IMS Institute for Healthcare 
Informatics, 2016). 
 These changes have not impacted all Americans equally. Mounting evidence suggests 
that women are significantly more likely to be prescribed medication than their male 
counterparts, even after adjusting for a number of gender-based health differences (Anthony et 
al., 2008; Skoog, Midlöv, Borgquist, Sundquist, & Halling, 2014; Thorell, Skoog, Zielinski, 
Borgquist, & Halling, 2012; Zhong et al., 2013). Approximately 47% of women between the 
ages of 15 and 44 report prescription medication use in the past 30 days, compared to just 26% 
of same-aged men (National Center for Health Statistics, 2016; Tinker, Broussard, Frey, & 
Gilboa, 2015). For nearly all drug classes, women receive more prescriptions than men (Anthony 
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et al., 2008; Schroder et al., 2016; Zhong et al., 2013), although these trends vary somewhat 
across the lifespan (Thorell et al., 2012; Zhong et al., 2013).  
For young women, the prescription gap appears to be even more pronounced. All ten of 
the most commonly prescribed drug classes for individuals under 30 are dispensed to women at 
higher rates than men, a trend that emerges in late adolescence and disappears by middle age 
(Schroder et al., 2016; Zhong et al., 2013). While contraceptive use and gender differences in 
morbidity seem to account for a large proportion of this difference (Skoog et al., 2014; Zhong et 
al., 2013), additional factors, such as gender differences in doctor’s prescribing patterns, may 
also be at play (Skoog et al., 2014). As overall prescribing rates continue to increase, more and 
more young women find themselves taking prescription medication on a regular basis (Tinker et 
al., 2015). 
Medication Adherence 
Defining Adherence. Increases in prescription medication use and the disproportionate 
rates of prescribing to young women emphasize the importance of medication adherence within 
this population. Defined by the World Health Organization (WHO) as “the extent to which a 
person’s behavior – taking medication, following a diet, and/or executing lifestyle changes, 
corresponds with agreed recommendations from a healthcare provider,” adherence is crucial for 
successful disease management (WHO, 2003, p. 3). Medication adherence is a key component of 
overall treatment adherence and involves taking medicines as prescribed. Failure to do so 
constitutes poor or suboptimal adherence, which can take several forms: under-adherence (taking 
less medication than prescribed), over-adherence (taking more medication than prescribed), or 
failing to follow provider instructions regarding how (e.g., with food) and when (e.g., morning, 
every four hours) to take medication. Although the term ‘compliance’ was often used in older 
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literature to reflect the same concept, more recent literature has tended to use the term 
‘adherence’ to avoid the implication of patient fault and reflect the active involvement of the 
patient in agreeing with provider recommendations (Hughes, 2004; Topinkova, Baeyens, Michel, 
& Lang, 2012). For the purpose of clarity, this paper will exclusively use the term ‘adherence.’ 
The Adherence Problem. Overwhelming evidence indicates that failure to take 
medication as prescribed can lead to a plethora of negative short- and long-term health outcomes. 
Former U.S. Surgeon General C. Everett Koop described the problem succinctly: “Drugs don’t 
work in people who don’t take them” (Osterberg & Blaschke, 2005, p.487). Suboptimal 
medication adherence is associated with poorer health, decreased quality of life, undesirable 
health consequences, and substantial increases in morbidity and mortality across numerous 
illnesses (Chowdhury et al., 2013; DiMatteo, Giordani, Lepper, & Croghan, 2002; Doggrell, 
2010; Hughes, 2004; Nunes et al., 2009; Simpson et al., 2006; Viswanathan et al., 2012). Failure 
to adequately adhere to prescription medication has been estimated to account for at least 10% of 
annual hospitalizations and approximately 125,000 medical deaths each year (Peterson, Takiya, 
& Finley, 2003; Viswanathan et al., 2012). In the United States, more than 1.53 million 
pregnancies can be attributed to imperfect adherence to oral contraceptives every year, 
representing nearly one-quarter of all pregnancies and more than half of all unintended 
pregnancies (Finer & Zolna, 2011; Guttmacher-Institute, 2016; Trussell et al., 2013a). Overall, 
poor adherence contributes to an estimated $290 billion in unnecessary annual healthcare 
spending in the United States alone (Golay, 2011; Nasseh, Frazee, Visaria, Vlahiotis, & Tian, 
2012; The New England Healthcare Institute, 2009).  
Unfortunately, suboptimal adherence to medication is incredibly common, particularly 
among patients with chronic health conditions, such as asthma, cancer, and diabetes (Chowdhury 
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et al., 2013; Coleman et al., 2012; Haynes, McDonald, Garg, & Montague, 2002; Rolnick, 
Pawloski, Hedblom, Asche, & Bruzek, 2013; Tomaszewski et al., 2014), and among those who 
require daily medication, such as women taking oral contraceptives (Molloy, Graham, & 
McGuinness, 2012; Trussell et al., 2013b; Wu, Kusunoki, Ela, & Barber, 2016). Nearly 55% of 
Americans report regular medication use (IMS Institute for Healthcare Informatics, 2016). 
However, an estimated 60% of prescriptions dispensed in the United States are not taken as 
prescribed, and more than half of patients taking long-term medication cease treatment within the 
first year, despite on-going need (Bosworth, 2011; Haynes et al., 2002; O’Connor, 2006). Large-
scale studies of pharmacy records indicate that 20-30% of prescriptions are never filled at all 
(Fischer et al., 2010; Gadkari & McHorney, 2010). This proportion is even higher for newly 
prescribed long-term medications (Gadkari & McHorney, 2010).  
Adherence in Young Women 
Young women may be at particular risk for poor adherence and subsequent negative 
outcomes. Convergent evidence from diverse patient populations suggests that overall, women 
are less likely to adhere to prescription medication than men (Chen, Lee, Liang, & Liao, 2014; 
Lee & Khan, 2016; Pai & Ostendorf, 2011; Puskas et al., 2011; Zhang & Meltzer, 2016). 
Furthermore, risk factors for poor adherence seem to differ somewhat between men and women, 
and suboptimal adherence among female patients is more likely to go unnoticed by healthcare 
providers (Chen et al., 2014; Holt et al., 2013; Puskas et al., 2011; Schuman-Olivier, Weiss, 
Hoeppner, Borodovsky, & Albanese, 2014). Notably, the gender discrepancy in medication 
adherence diminishes significantly among the elderly (Holt et al., 2013), suggesting that young 
women may be at disproportionate risk (Puskas et al., 2011).  
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This is underscored by generally high rates of poor adherence among adolescents and 
young adults. Compared to children, middle aged adults, and the elderly, young adults aged 18 to 
29 are significantly less likely to adhere to prescription medications, particularly when taken for 
extended periods of time (Becker, Dezii, Burtcel, Kawabata, & Hodder, 2002; Ettenhofer et al., 
2009; Hinkin et al., 2004; Hood, Peterson, Rohan, & Drotar, 2009). As many as three-quarters of 
young adults taking prescription drugs routinely fail to adhere to their medication, even with the 
knowledge that poor adherence may dramatically increase the risk of serious health problems 
(Fredericks et al., 2008; Hilliard, Wu, Rausch, Dolan, & Hood, 2013; Hood et al., 2009; 
McGrady, Williams, Davies, & Pai, 2014). For example, adolescent and young adult transplant 
recipients are four times more likely to be non-adherent to critical immunosuppressant drugs 
than adult recipients (Fredericks, 2008). Additional literature indicates that transition to college 
and corresponding increases in independence are particularly associated with declines in 
medication adherence (Butow et al., 2010; McGrady, Williams, Davies, & Pai, 2014; McGrady 
et al., 2015), even among previously adherent individuals (Butow et al., 2010; Hilliard, Wu, 
Rausch, Dolan, & Hood, 2013; Hood et al., 2009; McGrady, Peugh, & Hood, 2014; McGrady, 
Brown, & Pai, 2015). Given that young women are prescribed more medication than young men, 
and that women generally are at greater risk for poor adherence, young women in particular seem 
to be disproportionately vulnerable to suboptimal adherence.  
Health Outcomes. Although young women are prescribed medication at lower rates 
compared to middle-aged and older individuals (Morgan & Kennedy, 2010), the potential 
outcomes associated with poor adherence are no less detrimental. Evidence suggests that non-
adherent young adults are approximately two times and a half times more likely to be 
hospitalized than age-matched adherent patients, and are more likely to need additional surgery 
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then their adherent peers (Goodhand et al., 2013; McGrady & Hommel, 2013). Poor adherence is 
also associated with greater use of emergency health services and more frequent emergency 
department visits (McGrady & Hommel, 2013).  
In addition to increased healthcare usage, suboptimal adherence in adolescence and 
young adulthood has also been linked to poor disease management, greater illness progression, 
increased risk of adverse health events (e.g., transplant rejection/graft loss, unintended 
pregnancy, cancer relapse), and poorer health-related quality of life (Adolescent and Young 
Adult Oncology Progress Review Group, 2014; Axelsson et al., 2009; Bhatia et al., 2012; Canner 
et al., 2013; Dobbels et al., 2010; Kennard et al., 2004; McCormick King et al., 2014). For 
example, Type I diabetes control is lowest among individuals aged 18 and 19 (Bryden et al., 
2001; Bryden, Dunger, Mayou, Peveler, & Neil, 2003), and young women are at even greater 
risk for serious diabetes complications during this period (Bryden et al., 2001; Pyatak, Florindez, 
& Weigensberg, 2013). Similarly, young adults with asthma are significantly more likely to have 
unmet asthma control needs than other age groups (Friedman, Navaratnam, & McLaughlin, 
2010; Scal, Davern, Ireland, & Park, 2008). Among young adult recipients of pediatric kidney 
transplantations, more than 35% of patients lose a functioning kidney transplant within three 
years after transitioning out of pediatric care (Harden et al., 2012), with the greatest risk for graft 
loss due to poor immunosuppressant adherence among women aged 17 to 24 (Foster et al., 2015; 
Van Arendonk et al., 2013). In addition to the increased morbidity associated with chronic 
disease, women aged 18 to 24 also have the highest prevalence of unintended pregnancy of any 
age group, contributing to significant medical and emotional burden (Finer & Zolna, 2011, 
2014). As many as half of these unintended pregnancies are attributable to poor adherence to oral 
contraceptives (Finer & Zolna, 2014; Trussell et al., 2013a). Given the increased risk and 
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morbidity associated with poor adherence, it is perhaps unsurprising that non-adherent young 
adults also report lower health-related quality of life than their adherent peers (Axelsson et al., 
2009; Fredericks et al., 2008; Rothenberger, Becker, Breuer, & Döpfner, 2011). Furthermore, 
health-related quality of life is reliably lower in young women than young men (Axelsson et al., 
2009; Fredericks et al., 2008; Sundberg, Palmqvist, Tunsater, & Toren, 2009).   
Beyond the detrimental physical, emotional, and social effects of such serious health 
outcomes, poor adherence among young adults also contributes to substantially higher mortality 
rates among young adults with chronic illness than other age groups. For example, cancer 
survival rates for children under 15 are nearly two times higher than survival rates for 
adolescents and young adults, which is believed to reflect a significant drop in adherence to oral 
chemotherapies and prophylactic antibiotics among young adults (Adolescent and Young Adult 
Oncology Progress Review Group, 2014; Canner et al., 2013; Kennard et al., 2004). Similarly, 
death rates due to asthma are four times higher among adolescents and young adults than among 
children (Bergstrom et al., 2008), and pediatric transplant recipients are at greatest risk for post-
transplant mortality between ages 16 and 20 (Hayes, McCoy, Whitson, Mansour, & Tobias, 
2015). 
The serious health consequences and societal costs associated with poor adherence 
among adolescents and young adults generally, and young women in particular, highlights the 
need for a better understanding of women’s adherence patterns and identification of factors 
associated with poor adherence within this at-risk population. While a great deal of research has 
been dedicated to identifying risk factors that can act as potential barriers to optimal adherence 
among middle-aged and older adults (Gellad, Grenard, & Marcum, 2011; Topinkova et al., 2012; 
Yap, Thirumoorthy, & Kwan, 2015), comparatively little attention has been paid to adherence 
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patterns among young adults (Macdonell, Carcone, Naar-King, Gibson-Scipio, & Lam, 2015; 
Pyatak et al., 2013). This is true despite evidence that the period of life between ages 18 and 29, 
often referred to as “emerging adulthood,” appears to be a critical stage for medication adherence 
and the development of other long-term health behaviors.  
Emerging Adulthood 
First described by Arnett in the early 2000s, emerging adulthood refers to a “prolonged 
period of independent role exploration during the late teens and twenties…distinguished by 
relative independence from social roles and from normative expectations” (Arnett, 2000, p. 469). 
A growing body of literature supports the concept of emerging adulthood as a distinct period of 
neurobiological, psychological, and social development marked by high levels of self-focus and 
increasing autonomy (Arnett, Žukauskiene, & Sugimura, 2014; Arnett, 2000; Henin & Berman, 
2016; Tanner, 2016). This period is marked by transition and flux; emerging adults typically 
leave their home and parents, explore new social networks, and experience high levels of 
educational and occupational change (Arnett et al., 2014; Arnett, 2000).  
Emerging Health Behaviors. In addition to these life changes, emerging adulthood is 
also a critical period for health behavior development (Cho, 2016; Daw, Margolis, & Wright, 
2017; Frech, 2009; Nelson, Story, Larson, Neumark-Sztainer, & Lytle, 2008). A number of risky 
health behaviors, including tobacco use, binge drinking, risky sexual behavior, and poor nutrition 
become increasingly prominent during emerging adulthood (Centers for Disease Control and 
Prevention, 2016; Daw et al., 2017; Frech, 2009; Nelson et al., 2008). While these behaviors are 
detrimental in their own right, mounting evidence suggests that problematic health behaviors in 
young adulthood can also set up trajectories for increasingly poor health later in life (Arria et al., 
2016; Daw et al., 2017; Nelson et al., 2008).  
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For certain individuals, adoption of poor health behaviors in emerging adulthood sets the 
stage for unhealthy habits and increasing difficulty with health maintenance later in life (Cho, 
2016; Daw et al., 2017; Frech, 2009; Mumford, Liu, Hair, & Yu, 2013). Trajectories from 
emerging to later adulthood are different for men and women (Howard, Galambos, & Krahn, 
2010). Although young women experience slower declines in health behaviors during emerging 
adulthood (Frech, 2009), women who engage in poor health behaviors during this period seem to 
be more likely to experience negative health outcomes later in life (Mumford et al., 2013).  
Medication adherence. Although no studies to date have explored trajectories in 
medication adherence from emerging adulthood into later life, these findings suggest that poor 
adherence during this critical period may set up problematic habits that prove detrimental across 
the lifespan. Given the fact that emerging adults, particularly young women, are at increased risk 
for poor medication adherence (Butow et al., 2010; Hilliard et al., 2013; McGrady et al., 2015; 
Pai & Ostendorf, 2011), understanding the risk factors associated with poor adherence in this 
population is of critical importance.  
Risk Factors for Poor Adherence 
 Given the importance of emerging adulthood as a distinct developmental period, it is 
reasonable to suppose that young adults face a distinct set of risk factors for poor adherence. 
Certain prominent risk factors affecting children and adolescents remain relevant during 
emerging adulthood, while additional risk factors identified among middle-aged and older adults 
seem to take on increasing importance.  
For example, evidence suggests that the higher-order cognitive processes (e.g., planning, 
problem-solving, decision-making) known as executive functions play an important role in 
successful medication adherence among children and adolescents (Bagner, Williams, Geffken, 
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Silverstein, & Storch, 2007; Duke & Harris, 2014; Garvie et al., 2017; McNally, Rohan, Pendley, 
Delamater, & Drotar, 2010; O’Hara & Holmbeck, 2013). In contrast, by middle adulthood, 
executive functions are more solidly developed and show much less consistent association with 
adherence (Baek, 2014; Barclay et al., 2007; Diamond, 2014; Ettenhofer et al., 2009; Schutte, 
2006). Notably, executive functions continue to develop through emerging adulthood (Diamond, 
2014), suggesting that executive dysfunction may be an important risk factor for poor adherence 
in young adults (Gutierrez-Colina et al., 2016).  
At the same time, risk factors that are important among middle-aged adults but less 
prominent among pediatric populations, such as alcohol use, substance abuse, and poor sleep, 
seem to emerge as increasingly important for medication adherence young adults (Butow et al., 
2010; Griffith, Kumaraswami, Chrysanthopoulou, Mattocks, & Clark, 2017; Pyatak et al., 2013; 
Riegel et al., 2011). Similarly, with increasing independence, emerging adults are typically 
increasingly responsible for managing their own treatment (Pai & Ostendorf, 2011; Shifren, 
Furnham, & Bauserman, 2003). As such, factors related to medication regimen (e.g., number of 
medications, prescriber instructions, side effects) and personal beliefs about medications, may 
become more important without the guidance or oversight of a parent (Ingersoll & Cohen, 2008; 
Labig Jr., Zantow, & Peterson, 2005; McQuaid et al., 2012; Schaefer et al., 2017). 
Finally, a number of variables seem to be relevant for medication adherence across the 
lifespan. For example, psychological distress (e.g., depression, stress) is a prominent risk factor 
for poor adherence for both children and adolescents, and middle-aged and older adults (Bender, 
2006; Desai & Oppenheimer, 2011; Fontanella, Bridge, Marcus, & Campo, 2011; Mausbach, 
Schwab, & Irwin, 2015; Uthman, Magidson, Safren, & Nachega, 2014). Similarly, poor social 
support and perceived barriers to care negatively impact adherence regardless of age (Danziger-
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Isakov et al., 2016; George & Shalansky, 2007; Graça Pereira, Berg-Cross, Almeida, & Cunha 
Machado, 2008; Magrin et al., 2015; Miller & DiMatteo, 2013). These risk factors also appear to 
be important for medication adherence during emerging adulthood (Bryden et al., 2003; 
Macdonell et al., 2015; Pai & Ostendorf, 2011; Pyatak et al., 2013), although their impact among 
college-aged women has not been fully established. Young adulthood is a period of increased 
risk for the emergence of mood and anxiety disorders, with young women disproportionately 
affected, as well as a period of significant changes in social networks and healthcare engagement 
(Cho, 2016; Tanner, 2016). As such, these relationships may function differently for young 
women than other groups.  
While converging lines of evidence suggest a unique constellation of risk factors may be 
particularly relevant for college-aged women taking daily prescription medications, little 
research has focused on adherence in this population. Those studies conducted to date have 
tended to focus on specific medical populations (e.g., emerging adults with asthma, women 
taking oral contraceptives) rather than the intersection of two important demographic risk 
factors, age and gender.  
Current Study. Given the disproportionate prescribing rates for young women and the 
serious short- and long-term health consequences associated with poor adherence, it is important 
to identify how various risk factors may function in this population. As such, the current student 
aimed to explore the psychosocial correlates of poor medication adherence among a sample of 
college-aged women.  
Demographic, treatment-related, and physical and mental health-related variables were 
assessed. No demographic variables were expected to correlate with poor adherence. In keeping 
with the literature discussed above, it was hypothesized that women who reported suboptimal 
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adherence would also report: 1) more complex medication regimens, 2) more negative beliefs 
about medications, 3) more perceived barriers to taking medication as prescribed, 4) higher 
levels of psychological distress, 5) less social support, and 6) greater alcohol and substance use, 
7) poorer sleep quality, and 8) greater executive dysfunction. 
Methods 
Participants 
Participants were recruited from among the participant pool composed of students in 
introductory psychology courses, at a large public research university in New England. 1,928 
students completed the participant pool pre-screening questionnaire to determine eligibility. 
Participants were eligible to complete the study if they 1) were age 18 years or older, 2) could 
read and understand English, 3) self-identified as female, and 4) were currently prescribed a 
daily mediation. Daily prescription medication use was assessed via self-report with the 
question: “Are you currently prescribed a medication (including birth control) for daily use? Do 
not include vitamins or supplements unless they are prescribed by a healthcare provider.” 
Participants who answered in the affirmative and met the above criteria were deemed eligible. 
632 students met inclusion criteria for the study out of a total of 1,243 female students (50.8%). 
Of those, 186 women (29.4%) participated in the study. Three individuals (1.6%) did not report 
their gender and were subsequently excluded, leaving a final sample of 183 women.  
Procedures 
 Recruitment occurred from February 2017 to April 2017. Eligible participants accessed 
the study online via a unique URL, which connected them to the Sona-Systems participant pool 
management software (Sona-Systems, Ltd., 2017). Prior to any study procedures, participants 
were presented with an information page detailing the purpose and potential risks of the study. 
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Information was presented in chunks to facilitate understanding, and participants indicated their 
consent by selecting “I agree” on the final page.  
Following informed consent, participants completed study questionnaires via Qualtrics, a 
software tool to electronically collect and manage research data (Qualtrics, 2017). Participants 
remained anonymous throughout study procedures and received class credit in compensation. 
The survey concluded with local and national mental health resources for any participants who 
may have wanted additional support for symptoms of depression, stress, and/or substance use. 
The university’s Internal Review Board approved all study procedures and measures. 
Measures 
Demographics. Participants reported their age, race, ethnicity, sexual orientation, year in 
school, relationship/marital status, family income, living situation, employment status, health 
insurance, and religious affiliation. 
Medication Use. Participants also provided detailed information regarding their daily 
prescription medication use. For each of their daily medications, participants reported the 
medication name, dosage, number of times taken per day, and means of administration. Means of 
administration were selected from a list of common administration methods: by mouth in pill 
form; by mouth in liquid form; inhaled (e.g., inhaler, nasal spray); topical or onto skin; via 
injection; or via another method which participants described. For each medication, participants 
indicated whether there were additional instructions associated with taking that medication by 
selecting any relevant items from a list of common medication instructions (e.g., taking 
medication at specific time of day, taking medication with food). This list included an option to 
indicate uncertainty about whether their medication came with additional instructions. 
Participants were also provided with space to include any instructions for their medication that 
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were not included on the list. These questions provided a comprehensive assessment of the 
nature and complexity of participants’ medication regimens. 
 To assess the duration of their prescription, participants also reported how long they had 
been taking each of their prescription medications, in months. They also indicated the primary 
reason for taking each of their medications. Reason for prescription was selected from a list of 
common health concerns, including birth control; a chronic medical condition; ADD/ADHD; a 
mental health condition; sleep; or for another reason, which the participant described. 
Participants who indicated their medication was primarily for a chronic medical condition or 
mental health condition were asked to specify their condition. This list included an option to 
indicate uncertainty about the purpose of their medication.  
 After completing these questions for one medication, participants reported whether or not 
they were prescribed an additional daily prescription medication. If they reported another 
medication, they were prompted to complete the same assessment for each medication until they 
indicated no additional daily prescription medications. Once participants reported no additional 
medications, the survey advanced to the next questionnaire.   
Medication Adherence. Participants completed the Morisky Medication Adherence 
Scale-8 (MMAS-8; Morisky, Ang, Krousel-Wood, & Ward, 2008), a brief, eight-item scale that 
has been widely used to measure medication adherence among a variety of populations, 
including adolescents and young adults (Goodhand et al., 2013; Tan, Patel, & Chang, 2014). 
Items address a number of common reasons for sub-optimal adherence, such as: “Do you 
sometimes forget to take your pills?”, “Have you ever cut back or stopped taking your medicine 
without telling your doctor because you felt worse when you took it?”, and “Over the past two 
weeks, were there any days when you did not take your medicine?” Participants responded either 
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yes or no to each question, yielding a possible score from zero to eight, with higher scores 
indicative of more adherence problems. The MMAS-8 is psychometrically sound, with good 
sensitivity, specificity, concurrent validity, and internal consistency (Morisky et al., 2008; 
Oliveira-Filho, Barreto-Filho, Neves, & Lyra Junior, 2012). In the current study, Cronbach’s 
alpha for the MMAS-8 was acceptable at 0.71. 
Beliefs About Medication. Participants also completed the Beliefs about Medications 
Questionnaire (BMQ; Horne, Weinman, & Hankins, 1999). The BMQ consists of 18 items that 
load onto four factors: Specific-Concern (regarding the participant’s concerns about the long-
term or disruptive effects of their current medication); Specific-Necessity (regarding the 
perceived necessity of the medication to the participant’s health); General-Overuse (regarding 
the participant’s beliefs that medications are overused by doctors); and General-Harm (regarding 
the participant’s beliefs that medicines are generally harmful/addictive and should not be taken 
continuously). Each item is rated on a one (Strongly Disagree) to five (Strongly Agree) scale, 
with higher scores indicating more negative views toward medications. The BMQ has been 
found to have good reliability, criterion-related, and discriminant validity, and has proven useful 
in a number of clinical populations (Horne et al., 1999). Cronbach’s alpha for the BMQ in our 
study was good,  = 0.87.  
Perceived Barriers to Adherence. Participants completed the Adolescent Medication 
Barriers Scale (ABMS), a 17-item self-report measure that assessed perceived barriers to 
adherence, including disease frustration, ingestion issues, and regimen complexity (Simons & 
Blount, 2007). Items included, “I feel that taking my medicine gets in the way of my activities,” 
and, “I’m not organized about when and how to take the medication.” Items were rated on a 
scale from one (Strongly Disagree) to five (Strongly Agree), with higher scores on each item 
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indicating stronger influence/importance of that specific barrier. Total barriers were assessed by 
summing the number of items on which participants indicated a score of four or more (agree or 
strongly agree). The AMBS has demonstrated high reliability and validity, and is particularly 
well-suited for use with young adults (Simons & Blount, 2007). Internal consistency in the 
current study was excellent,  = 0.91. 
Depression. Participants completed the Center for Epidemiological Studies – Depression 
scale (CES-D), a self-report, 20-item measure of depressive symptoms (Radloff, 1977). Items 
include: “I felt that everything I did was an effort,” “I thought my life had been a failure,” and “I 
felt hopeful for the future” (reverse-coded). The CES-D assesses depressed mood in the previous 
week on a four-point scale ranging from zero (Rarely/None of the time (less than one day)) to 
three (Most/ All of the time (5-7 days)). Higher scores on the scale indicate increased presence of 
depressive symptoms. Scores of 16 or higher are considered indicative of clinically significant 
depression. The instrument has demonstrated high internal consistency, as well as strong 
construct validity (Eaton, Muntaner, Smith, Tien, & Ybarra, 2004; Radloff, 1977). Internal 
consistency in the current study was good (Cronbach’s alpha = 0.81). 
Perceived Stress. Participants also reported their level of perceived stress. The Perceived 
Stress Scale (PSS; Cohen, Kamarck, & Mermelstein, 1983) was developed to measure the degree 
to which situations in one’s life are perceived as stressful. Participants were asked to consider the 
last month when responding to ten questions, such as “How often have you been upset because 
of something that happened unexpectedly?” and “How often have you felt that you were on top 
of things?” (reverse-coded). Participants respond to questions on a five-point scale ranging from 
“never” to “very often.”  The PSS is not a diagnostic instrument, thus there are no cut-off scores 
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and comparisons are sample dependent. The scale has demonstrated good test-retest reliability (r 
= 0.85; Cohen et al., 1983). Cronbach’s alpha was excellent ( = 0.90) for the current sample. 
Social Support. Participants completed the twelve-item Interpersonal Support Evaluation 
List (ISEL; Cohen & Hoberman 1983) to measure their perceptions of social support. Items 
included, “If I wanted to have lunch with someone, I could easily find someone to join me,” and 
“I feel that there is no one I can share my most private worries and fears with” (reverse-scored). 
Questions were answered on a four-point scale ranging from “definitely true” to “definitely 
false.” The ISEL is not a diagnostic measure, so no clinical thresholds are applied to total scores. 
When using a college sample, the scale has demonstrated adequate validity and reliability 
properties (Cohen & Hoberman, 1983). Internal consistency in our sample was good, at  = 0.80.  
Alcohol Use. The ten-item Alcohol Use Disorders Identification Test (AUDIT) assessed 
for alcohol dependence and problematic alcohol use. Participants self-reported their drinking 
behaviors (e.g., “How often do you have a drink containing alcohol?”, “How often do you have 
six or more drinks on one occasion?”), as well as any alcohol-related functional impairment (e.g., 
“How often in the last year have you failed to do what was normally expected of you because of 
drinking?”). Questions are anchored on a five-point Likert scale, with responses for most 
questions ranging from “never” to “daily or almost daily.” The psychometric properties of the 
AUDIT are favorable, with a high degree of internal consistency (Reinert & Allen, 2007). In our 
sample, AUDIT internal consistency was acceptable (Cronbach’s alpha = 0.72). 
Substance Use. Participants self-reported their substance use with the Drug Abuse 
Screening Test-10 (DAST-10; Skinner, 1982). The DAST-10 is a ten-item measure used to 
assess drug use and related problems. Items include, “Are you unable to stop abusing drugs when 
you want to?” and “Do you ever feel bad or guilty about your drug use?” For each question, 
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participants indicate either “yes” or “no,” yielding a score from zero to ten, with higher scores 
consistent with more drug-related problems. Scores of six or more are consistent with substantial 
problems related to drug abuse, and scores of three or more warrant additional clinical attention. 
Internal consistency for the DAST-10 in our sample was low,  = 0.62. 
Sleep Problems. Participants’ sleep was assessed using the DSM-5 Level 2 Sleep 
Disturbance Measure (PROMIS Health Organization and PROMIS Cooperative Group, 2012) 
and the Pittsburgh Sleep Quality Index (PSQI; Buysse, Reynolds, Monk, Berman, & Kupfer, 
1989). The DSM-5 Level 2 Sleep Disturbance Measures consists of eight self-report items that 
assess sleep quality and disturbances over the past week. Items describe various problems with 
sleep (e.g., “I had difficulty falling asleep,” “I had difficulty staying asleep”), and are rated on a 
one (Never/Not at all bothered) to five (Always/Very much bothered) scale. Higher scores 
indicate greater symptom frequency and interference, and can be converted to T-scores to allow 
for standardized severity ratings (PROMIS Health Organization and PROMIS Cooperative 
Group, 2012). In the current study, Cronbach’s alpha was acceptable,  = 0.72. 
The PSQI is a self-rated nine-item questionnaire that assesses sleep patterns, quality, and 
disturbances and provides a rating from ‘poor’ to ‘good’ across seven domains: sleep duration, 
sleep disturbances, sleep latency, functional impairment due to disturbed sleep, sleep efficiency, 
overall sleep quality, and the use of medications to sleep. The PSQI also provides a global score 
and thresholds for determining clinical significance. It has been used extensively for sleep 
research in a wide range of community and clinical populations, has high internal consistency 
and good construct validity (Buysse et al., 1989; Buysse et al., 2008). Internal consistency for the 
PSQI in the current study was acceptable (Cronbach’s alpha = 0.74). 
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Executive Functioning. Participants completed the adult self-report version of the 
Behavior Rating Inventory of Executive Function (BRIEF-A; Roth, Isquith, & Gioia, 2014). The 
BRIEF-A consists of 75 items, each of which describes an issue related to poor executive 
functioning, and asks how often in the last month each issue has been a problem for the 
participant – “Never (0)”, “Sometimes (1)”, or “Often (2)”. The BRIEF-A yields two broad 
domain scores. The Behavioral Regulation domain includes subscales that tap into the 
participant’s ability to regulate their own behavior. The Metacognition domain includes 
subscales that deal with the participant’s ability to exert effortful control over her own mental 
processes in order to organize her activities and environment. These two domain scores can also 
be summed to yield an overall Global Executive Composite (GEC) score. The BRIEF-A has 
strong psychometric properties and has been found to be useful in young adult populations 
(Ciszewski, Francis, Mendella, Bissada, & Tasca, 2014; Roth et al., 2014; Roth, Lance, Isquith, 
Fischer, & Giancola, 2013). In our sample, Cronbach’s alpha was excellent at  = 0.97.  
Data Management and Analyses 
 Study data was collected and stored online using Qualtrics research software (Qualtrics, 
2017). At the end of data collection, data was downloaded to a secure password-protected 
computer. Before conducting any analyses, data was cleaned for clarity and consistency. 
Participant-reported reasons for taking a medication were verified and re-coded as appropriate. 
For example, if a participant reported that they were taking a medication for “Another Reason,” 
and reported that their medication was for hypothyroidism, their reason was re-coded as “A 
Chronic Medical Condition.” A complete summary of data re-coding is presented in Appendix 
A.  
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All analyses were conducted using SPSS Statistics software package, version 24.0. 
Sample characteristics were assessed using frequency counts and descriptive statistics. 
Demographic, medication-related, and behavioral/psychosocial risk factors were assessed using 
Pearson’s correlation coefficients, independent-samples t-tests, and one-way analyses of variance 
(ANOVAs). Preliminary analyses were conducted to confirm statistical assumptions of 
normality, linearity, and equality of variance, as appropriate. Finally, a series of hierarchical 
linear regressions were conducted to assess the predictive validity of medication-related and 
behavioral/psychosocial risk factors after controlling for demographic variables that were 
significantly related to adherence. Significance was assessed at the p < 0.05 level for all analyses, 
except where Holm’s sequential Bonferroni procedure was applied, as necessary, to adjust for 
multiple comparisons (Holm, 1979).  
Results 
 
Sample Demographics 
 Participant demographics are summarized in Table 1. The mean age of participants was 
19.38 years (SD = 2.44, range = 18-49). As previously noted, 100% of participants self-identified 
as female. The majority (73.2%) of participants identified as White or European American, 
13.7% identified as Hispanic or Latina, 12% identified as Asian or Asian American, 8.7% 
identified as Black or African American, 0.5% identified as Native American, and 2.2% 
identified their race as “Something Else.” 9.8% of participants selected more than one 
racial/ethnic identity. A large majority (93.4%) of the sample identified as straight or 
heterosexual. An additional 4.9% of the sample identified as bisexual, 0.5% identified as lesbian, 
and the remaining 1% of participants responded either that they were unsure of their sexual 
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orientation or endorsed their sexual orientation as “Something Else.” The sample was composed 
primarily of freshmen (39.3%) and sophomores (34.4%). An additional 20.2% of participants 
were juniors, 5.5% were seniors, and 0.5% reported being in their fifth year at the university.  
The majority (83.7%) of the sample reported living on campus, with the remaining participants 
fairly evenly divided between those living off-campus (8.7%) and those living at home with 
family (8.2%). Most participants (61.1%) reported a family income greater than $80,000 per 
year. 10.6% reported an annual family income between $60,000 and $80,000, 11.7% reported a 
family income between $40,000 and $60,000, 7.8% reported a family income between $20,000 
and $40,000, 4.4% reported a family income between $10,000 and $20,000, and 4.4% reported a 
family income of less than $10,000 per year. 99% of participants reported health insurance 
coverage; 65% were covered through family, 15.8% were covered through work, 3.3% were 
covered through school, and 14.9% were covered through a public insurance provider (e.g., 
Medicaid). The remaining 1% of participants did not report their health insurance coverage. The 
majority of participants reported some employment; 39.9% reported having a part-time job, 
37.7% reported having a summer job, and 0.5% reported working full-time. 21.3% reported that 
they were not employed, and an additional 0.5% did not report their employment status.  
Medication Usage 
  Participant medication usage is presented in Table 2. Participants reported taking an 
average of 1.48 daily prescription medications (SD = 0.85, range = 1-7). The modal number of 
daily medications was one (65% of participants). An additional 24% of participants reported 
taking two daily medications, 6.6% reported taking three, 1.6% reported taking four, and 0.5% 
reported taking five and seven, respectively, for a total of 265 distinct medications across the 
entire sample. Medication data was missing for three participants. Participants reported 
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medication regimens involving an average of 2.66 medication-related instructions per participant 
(SD = 2.19, range 1-13), with an average of 1.81 (SD = 1.14) instructions per medication. A 
minority (13%) of participants reported being bothered by unpleasant side effects of their 
medication. 
More than three-quarters (78.7%) of the sample reported taking daily medication for birth 
control. 14.8% reported taking medication for a chronic medical condition, 16.9% reported 
taking medication for a mental health condition, 6.6% reported taking medication for 
ADD/ADHD, 1.6% reported taking medication for sleep, and 5.5% reported taking medication 
for another reason. No participants reported being unsure of the primary reason for taking their 
medication. Medications were overwhelmingly administered orally, in pill form (94% of all 265 
medications). An additional 0.4% were administered orally in liquid form, 2.6% were inhaled, 
1.9% were administered topically, and 0.8% were administered via injection. 0.4% were 
administered via another method. Medication characteristics are presented in Table 3. 
Clinical Features   
 Descriptive statistics for the scales assessing potential risk factors are presented in Table 
4. For scales with clinical thresholds, the number and percentage of participants who reported 
clinically-relevant levels of distress are also reported in Table 4. Participants reported generally 
low levels of concerns about the long-term effects of their own medications (BMQ Specific 
Concerns: M = 9.06, SD = 4.10) and low perceived necessity of their medications (BMQ 
Specific Necessity: M = 10.87, SD = 5.57). They also reported generally positive attitudes 
toward the use (BMQ General Overuse: M = 10.87, SD = 3.62) and safety (BMQ General Harm: 
M = 7.95, SD = 2.60) of medications. Perceived barriers to adherence were also relatively low, 
although there was significant variability in the sample (M = 2.70, SD = 2.96, range = 0-11).  
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 Participants reported elevated levels of depressive symptoms (M = 19.72, SD = 12.13), 
and more than 46% scored above the clinical cut-off indicative of major depression. Participants 
also reported elevated stress levels (M = 17.67, SD = 7.65). Depression symptoms and perceived 
stress were highly correlated (r = 0.802, p < 0.001), and were therefore condensed into a single 
composite “Distress” scale for subsequent analyses. This composite scale consisted of the 
summed z-scores of both scales. On average, participants in our sample reported moderate levels 
of perceived social support (M = 31.54, SD = 5.40).  
 Participants reported low levels of alcohol-related problems on average (M = 6.13, SD = 
3.81), although approximately 25% scored above the clinical cut-off for potential alcohol abuse. 
Substance use and related problems were rare in our sample (M = 0.060, SD = 0.99), with only 
5.6% of participants meeting clinical thresholds for drug-related concerns.  
 On average, participants reported minimal sleep disturbance (M = 20.19 (T-score of 51), 
SD = 5.24), and a minority (5.6%) reported clinically relevant levels of sleep problems. Overall 
sleep quality on the PSQI was rated in the “fairly good” range, and daytime dysfunction was 
rated as “only a slight problem.”   
 Overall, global executive functioning in our sample was within normal limits based on 
participants’ age (M = 109.19 (T-score = 52), SD = 27.24). Average scores for the domains of 
Behavioral Regulation (M = 47.77 (T-score = 53), SD = 12.75) and Metacognition (M = 61.34 
(T-score = 51), SD = 16.22) were also in the average range. 13% of participants endorsed 
clinically significant levels of executive dysfunction.    
Medication Adherence 
 Participants endorsed an average of 3.30 (SD = 1.71, range 0-8) out of a total of eight 
possible problems related to adhering to their daily prescription medication, and 94% of 
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participants endorsed at least one problem with adherence. A breakdown of reported problems is 
presented in Table 5. The most commonly endorsed adherence problems included sometimes 
forgetting to take one’s medication (72.7%), forgetting to bring one’s medication when leaving 
home (59.6%), having missed at least one dose within the past two weeks (43.7%), and 
struggling to remember to take one’s medication (40.9%). Participants also reported feeling 
hassled for having to take their medication (22.4%), stopping their medication because it made 
them feel worse (18.6%), stopping their medication because them felt better (10.9%), and failing 
to take their medication the day before (7.7%). 
Demographic Risk Factors. Relationships between adherence problems and 
demographic variables were assessed using Pearson’s correlation coefficients, independent 
samples t-tests, and ANOVAs, as appropriate. Age was not significantly correlated with MMAS-
8 scores (r = -0.077; p = n.s.). Because women were able to select more than one racial/ethnic 
identity, separate independent samples t-tests were conducted for each racial/ethnic identity, 
comparing women who endorsed that identity with women who did not. Women who identified 
as Hispanic/Latina reported significantly more problems with adherence than women who did 
not identify as Hispanic/Latina (t (176) = -2.191, p = 0.019). No other racial or ethnic identity 
was associated with greater adherence problems (all p’s > 0.05). Similarly, adherence scores did 
not significantly differ by sexual orientation, year in school, living situation, family income, 
health insurance coverage or employment status (all p’s > 0.05).  
Medication-Related Risk-Factors. Relationships between adherence problems and 
medication-related variables were assessed using independent samples t-tests and Pearson’s 
correlation coefficients. Because women were able to select more than one reason for taking 
their medication, separate t-tests were conducted for each primary reason, comparing women 
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who endorsed taking at least one medication for a given reason to those who did not endorse 
taking any medications for that reason. None of the reported reasons were associated with greater 
MMAS-8 scores (all p’s > 0.05).  
Due to the high proportion of women in our sample taking oral contraceptives, an 
ANOVA was conducted to assess for potential differences in adherence between women taking 
medication for birth control only (n = 93), women taking medications for birth control and other 
reasons (n = 49), and women taking medications other than birth control (n = 36). There were no 
significant differences in adherence problems across these groups (F (2, 174) = 1.432, p = n.s.)  
Regimen Complexity. Correlation coefficients for medication-related variables are 
reported in Table 6. A complete correlation matrix of study variables is included in Appendix B. 
Neither participants’ total number of medications (r = -0.045; p = n.s.) nor the total number of 
instructions associated with their medication regimens (r = -0.005; p = n.s.) were significantly 
correlated with MMAS-8 scores.  
Beliefs about Medication. Problems with adherence were significantly associated with 
self-reported concerns about one’s own medications (r = 0.225; p = 0.004); women who reported 
more concerns about their medication (e.g., “I sometimes worry about the long-term effects of 
my medicine”) also reported more problems adhering to their daily prescription. However, 
adherence problems were not significantly related to the perceived necessity of one’s own 
medications (r = 0.038; p = n.s.), or to general concerns about medication overuse (r = 0.014; p = 
n.s.) or harmfulness (r = 0.060; p = n.s.).  
Perceived Barriers to Adherence. There was a medium-to-large correlation between the 
total number of self-reported barriers to adherence and MMAS-8 scores (r = 0.453; p < 0.001), 
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such that women who reported more barriers (e.g., “I do not want other people to notice me 
taking the medicine”) also reporting more problems with adherence.  
Behavioral and Psychosocial Risk Factors. Relationships between MMAS-8 scores and 
behavioral and psychosocial variables were also assessed using Pearson’s correlation 
coefficients. Results are presented in Table 7.   
Psychological Distress. Psychological distress significantly correlated with MMAS-8 
scores (r = 0.264; p = 0.001). Women who reported more severe distress (i.e., depressive 
symptoms and perceived stress) also reported more problems adhering to their medication. The 
effect size for the association between distress and adherence was small. Women who reported 
clinically significant levels of depressive symptoms reported significantly more problems with 
adherence (t (172) = 3.642, p < 0.001). 
Social Support. A small, negative correlation between social support and MMAS-8 
scores problems was observed (r = -0.205; p = 0.008). Women who reported greater social 
support reported significantly fewer problems with medication adherence. 
Alcohol and Substance Use. There was a small, positive association between alcohol use 
and medication adherence (r = 0.167; p = 0.042), but no significant relationship between 
adherence and substance use problems (r = 0.103; p = n.s.). Women who reported clinically 
significant levels of alcohol-related or substance use-related problems did not report significantly 
more problems with adherence (alcohol: t (166) = -1.550, p = n.s.; substance use: t(170)= -1.009, 
p = n.s.). 
Sleep Problems. Greater sleep disturbance, as measured by the DSM-5 Sleep Disturbance 
Measure, was significantly associated with more adherence problems (r = 0.151; p = 0.047). The 
effect size for the association between sleep problems and adherence was also small. Women 
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who reported clinically significant levels of sleep disturbance did not report significantly more 
problems with adherence (t (173) = -0.943, p = n.s.). 
Executive Functioning. Greater executive dysfunction was significantly associated with 
more adherence problems (r = 0.317; p < 0.001); women who reported more difficulties with 
executive functioning also reported more problems with medication adherence. The association 
between executive functioning and adherence was of medium effect size. 
Predicting Adherence. A series of hierarchical linear regressions predicting MMAS-8 
scores from medication-related and behavioral/psychosocial risk factors controlled for ethnicity 
(i.e., Hispanic/Latina vs. not Hispanic/Latina). Separate analyses were conducted for each risk 
factor found to be significantly correlated with adherence, as discussed above. Beta-weights and 
R2 values for the addition of each risk factor to the model are listed in Table 8. Due to multiple 
tests, significance is indicated based on adjusted  levels. 
Concerns about the long-term effects of one’s own medications significantly predicted 
higher MMAS-8 scores ( = 0.207, p = 0.007), and accounted for an additional 4.2% of the 
variance in adherence problems beyond the variance associated with demographics (F(2, 163) = 
6.995, p = 0.001). Self-reported barriers to adherence also significantly predicted MMAS-8 
scores ( = 0.401, p < 0.001), and accounted for an additional 16% of the variance in adherence 
problems after controlling for ethnicity (F(2, 166) = 19.537, p < 0.001). Similarly, high 
psychological distress significantly predicted high MMAS-8 scores ( = 0.250, p = 0.001), and 
accounted for an additional 6.1% of the variance in adherence scores after controlling for 
demographics (F(2, 166) = 8.894, p < 0.001). Social support was also a significant predictor, 
with higher perceived social support predicting fewer problems with adherence ( = -0.193, p = 
0.011). Social support scores accounted for an additional 3.7% of the variance in MMAS-8 
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scores after controlling for demographics (F(2, 166) = 5.563, p = 0.005). In contrast to the initial 
correlational findings, alcohol use ( = 0.155, p = n.s.) and sleep disturbance ( = 0.135, p = n.s.) 
were no longer significant predictors. However, global executive functioning was a significant 
predictor of MMAS-8 scores ( = 0.300, p < 0.001), and accounted for an additional 8.7% of the 
variance in adherence problems after controlling for demographics (F(2, 148) = 9.046, p < 
0.001). 
Results for the inclusion of these variables in a single regression model are presented in 
Table 9. When the identified risk factors were included in a single step of the regression model, 
after controlling for Hispanic/Latina ethnicity, the added variables accounted for an additional 
26.1% of the variance in adherence problems (𝜒2 = 5.728, p < 0.001). Perceived barriers ( = 
0.416, p < 0.001) and global executive functioning ( = 0.269, p = 0.024) remained as significant 
predictors. All other included variables were non-significant when entered simultaneously. 
Discussion 
 The current study sought to evaluate the psychosocial correlates of poor adherence to 
daily prescription medication among women at a large public research university in New 
England. Specifically, the study assessed the prevalence of adherence problems among this 
emerging adult population, and identified psychosocial variables associated with poor adherence.  
Consistent with previous findings, self-reported problems with adherence were the norm 
in our sample, with nearly all participants (94%) reporting at least one problem adhering to their 
medication. Unintentional non-adherence due to forgetting was cited most frequently (90%), 
although a significant portion of the sample also reported intentional non-adherence (23%).  
Women in our sample who identified as Hispanic/Latina reported significantly more 
adherence problems than women who did not identify as Hispanic or Latina. Although we did 
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not anticipate that demographic variables would be associated with adherence problems, this 
finding is consistent with previous research in which Hispanic/Latina identity has been 
associated with poor treatment adherence among clinical samples of middle-aged and older 
adults (González & Borrayo, 2011; Mansyur, Rustveld, Nash, & Jibaja-Weiss, 2015; Rashid et 
al., 2017).  
The hypothesized relationship between more complex medication regimens and more 
problems with adherence was not observed in our sample. This finding is likely a reflection of 
the relatively low medication burden in our sample; most participants reported taking just one 
daily medication, with relatively few associated instructions. In contrast, most adherence studies 
among young adults focus on clinical populations with complex medication regimens, and show 
significant associations between regimen complexity and adherence problems (Foster & Pai, 
2014; Hanghøj & Boisen, 2014; Ingersoll & Cohen, 2008). Thus, our results suggest that among 
community samples of young women, regimen complexity may only become relevant to 
adherence when medication burdens are particularly high.  
We also hypothesized that negative beliefs about medications would significantly predict 
greater problems with adherence. This hypothesis was only partially supported in our sample. 
Only specific concerns about the safety and long-term effects of one’s own medications 
significantly predicted poor adherence; beliefs about the necessity of one’s own medications and 
general concerns about medication overuse or harmfulness were unrelated to self-reported 
adherence problems. This was true despite the fact that participants reported generally low levels 
of concerns about their own medications. These findings demonstrate that young women’s 
concerns about their medications seem to play a more important role in adherence than other 
negative medication beliefs, and suggest that even low levels of specific concerns in the context 
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of generally positive medication beliefs may negatively impact adherence in emerging 
adulthood.   
Consistent with our hypothesis, the number of self-reported barriers to adherence 
significantly predicted problems with adherence, even after controlling for Hispanic/Latina 
ethnicity. When added to the regression model, perceived barriers accounted for considerable 
proportion (16%) of the variability in adherence scores, and perceived barriers remained a 
significant predictor even when risk factors were tested simultaneously. These results are 
consistent with previous studies of adherence in young adults (Danziger-Isakov et al., 2016; Lee 
et al., 2014; Simons & Blount, 2007), and underscore the importance of young women’s 
perceptions about the difficulty of adhering to their medications on their actual health behaviors.  
Our prediction that higher levels of psychological distress would significantly predict 
poor adherence was also supported in our sample. Distress scores accounted for approximately 
6% of the variance in adherence problems, after controlling for ethnicity, and women who scored 
above clinical cut-offs on a measure of depressive symptoms reported significantly more 
problems taking their medications as prescribed. These findings add to the existing literature 
identifying psychological distress and depression as major risk factors for poor medication 
adherence in emerging adulthood (Butow et al., 2010; Hilliard et al., 2013; Penkower et al., 
2003; Pyatak et al., 2013), and suggests that this relationship is important in community samples 
of young women.   
As hypothesized, lower levels of social support were also predictive of greater problems 
with adherence. Perceived social support accounted for a small but significant proportion (3.7%) 
of the variance in adherence scores after controlling for Hispanic/Latina identity. Thus, although 
emerging adulthood is often a period of considerable social flux (Arnett et al., 2014), our data 
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indicate that support networks remain important for successful medication adherence throughout 
this developmental stage. 
Contrary to our predictions, elevated levels of alcohol and substance use were not risk 
factors for poor adherence in our sample after controlling for demographics, even to the extent 
that women who reported clinically significant levels of alcohol and substance use problems did 
significantly differ on adherence scores. This may be due to the relatively low levels of alcohol-
related problems and substance use in our sample. The lack of a significant relationship between 
alcohol and substance use and problems with adherence may also reflect distinct associations of 
health behaviors among college students. Drinking culture is pervasive on American college 
campuses (White & Hingson, 2013), and alcohol consumption patterns among college students 
typically differ significantly from consumption patterns among other populations. For example, 
baseline levels of alcohol use are significantly higher among college students than individuals in 
other age groups, and drinking typically occurs in social context (Arria et al., 2016). As such, the 
relationship between alcohol use and poor adherence to medication observed in other young 
adult populations, particularly clinical populations, may not hold true for a community sample of 
college women (Bender, 2006; Griffith et al., 2017; Pyatak et al., 2013).  
Similarly, the hypothesized relationship between sleep problems and poor adherence was 
not significant in our sample after controlling for ethnicity, and clinically significant levels of 
sleep disturbance did not significantly impact problems with adherence. As with the lack of 
association between alcohol use and adherence, this finding may be attributable to the minimal 
sleep disturbances reported by women in our sample, which may have precluded a robust 
relationship. Given that sleep patterns among college students also tend to vary significantly 
from patterns among non-college adults (Lund, Reider, Whiting, & Prichard, 2010), it may also 
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be the case that these relationships simply do not hold in among college women as they do in 
other populations (Riegel et al., 2011). 
Greater executive dysfunction was shown to be a significant predictor of adherence 
problems in our sample, consistent with study hypotheses. Despite the fact that, on average, 
women in our sample fell within normative limits for executive functioning, those who reported 
more EF difficulties also reported more problems with medication adherence. Global executive 
functioning scores accounted for a significant proportion of variation in adherence after 
controlling for demographics, and executive functioning remained a significant predictor even 
when risk factors were tested simultaneously. These findings support the idea that executive 
functioning makes a significant contribution to medication adherence in emerging adulthood, 
even among a community sample with minimal reported dysfunction.  
To our knowledge, this is the first study to establish these psychosocial/adherence 
relationships among a community sample of young women. These findings suggest a unique 
constellation of risk factors at play for college-aged women taking daily medication, which does 
not map clearly onto the risk factors for children and younger adolescents or middle-aged and 
older adults. Thus, our results lend additional support to the concept of emerging adulthood as a 
distinct period of life for health-related behaviors. Furthermore, the particular pattern of risk 
factors in our sample indicates that age and gender may interact in unique ways, such that 
findings related to medication adherence in other populations may not generalize to college 
women. This is particularly important given the high rates of prescribing (more than half of the 
1,243 women in the participant pool reported taking a daily medication), the negative outcomes 
associated with poor adherence among young women, and the potential for poor adherence in 
emerging adulthood to set up problematic adherence trajectories into later life.  
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Limitations 
Despite the novelty and clinical importance of these findings, a number of limitations are 
worth noting. First, as with most adherence studies among young adults, data in this study are 
cross-sectional, and preclude any claims of causality. It may be the case that poor adherence to 
medication has a significant negative impact on psychosocial factors (e.g., psychological 
distress, sleep, executive functioning), or that the relationship between adherence and these 
variables is bidirectional. Furthermore, it is not clear how the variables assessed here may 
influence adherence over time. Future studies should consider collecting longitudinal data to 
address this significant gap in the literature and may better inform clinical interventions. 
Second, this study was conducted online, and relied wholly on self-report. While this 
methodology allowed for broader reach and the inclusion of women who may not have been able 
or willing to participate in a face-to-face study, the online format also limited the extent to which 
we were able to regulate the environment in which participants completed the survey, which may 
increase the risk for inconsistent engagement or lack of attention to the questions. In addition, 
self-reports can be prone to recall errors and social desirability bias. These factors can lead to 
underestimates of adherence problems when compared to more objective measures (Lehmann et 
al., 2014; MacLaughlin et al., 2005; Shi et al., 2010; Williams et al., 2013). The self-report 
nature of the additional measures also raises the possibility that social desirability and demand 
characteristics may also have impacted self-reports of mood symptoms, alcohol and substance 
use, and sleep problems.  
Finally, this study used a measure of adherence problems, rather than a direct measure of 
adherence itself. While the MMAS-8 has been shown to be highly sensitive to poor adherence 
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(Morisky et al., 2008), it may be the case that it does not map precisely onto other metrics of 
suboptimal adherence (e.g., missed doses).  
Future Directions 
 The results of our study emphasize the importance of studying adherence problems 
among community populations, particularly under-studied demographics like young adults. 
Given the uniqueness of our sample, additional research is also necessary to extend these 
findings to other young adults, and identify potential risk factors for poor adherence among 
college men, as well as emerging adults outside a university setting.  
The high rates of problems with adherence in our sample suggest that adherence among 
emerging adults is a significant clinical concern, but may be likely to go undetected in 
community samples of generally healthy individuals. This is particularly problematic given the 
serious consequences associated with poor adherence among young women, including illness 
progression, unintended pregnancy, and poor disease management (Adolescent and Young Adult 
Oncology Progress Review Group, 2014; Axelsson et al., 2009; Dobbels et al., 2010; Finer & 
Zolna, 2011). Future research is needed to develop and test screening procedures for identifying 
poor adherence among college women and other young adults. By identifying patients who may 
be at risk for suboptimal adherence, prescribers can provide greater support around medication-
taking behaviors. The high rates of adherence problems observed in this sample, and the growing 
literature on the emergence of health behavior trajectories in young adulthood suggests that 
emerging adulthood may be an optimal time to deliver adherence interventions in order to 
maximize their long-term effectiveness. 
Adherence has been described as “the most important therapeutic factor” for patients 
taking prescription medications (Arlt, Linder, Rosler, & von Renteln-Kruse, 2008, p.1034), and 
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meta-analytic evidence suggests that improving medication adherence may have a greater impact 
on clinical outcomes than novel treatment advances (Haynes, Ackloo, Sahota, McDonald, & 
Yao, 2008). As such, understanding barriers to adherence can help to improve clinical practice 
and inform future interventions. Interventions tailored to the risk factors most relevant for young 
women, including concerns about their medications, perceived barriers, poor executive 
functioning, psychological distress, or poor social support may prove be more effective than 
interventions developed for other populations.  
Finally, as noted above, future research should prioritize longitudinal studies that assess 
the relationships between risk factors and adherence over time. To date, nearly all the adherence 
literature for young adults is based on cross-sectional data, which limits our ability to understand 
causal processes and the potential bidirectional relationships between psychosocial factors and 
health behaviors.  
Conclusions 
 Convergent lines of evidence have suggested that emerging adulthood may be a time 
during which individuals, particularly young women, are at increased risk for poor medication 
adherence and associated health problems. This study sought to identify potential risk factors for 
adherence problems among a large sample of college women via an extensive online survey. 
Among college women, a number of factors were associated with adherence problems, including 
Hispanic/Latina identity, concerns about the long-term safety and effectiveness of their 
medications, perceived barriers to consistent adherence, poor executive functioning, 
psychosocial distress, and low levels of social support. Contrary to our hypotheses, regimen 
complexity, negative beliefs about medications broadly, greater alcohol and substance use, and 
sleep problems were not significantly associated with adherence problems. Our findings suggest 
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a unique set of risk factors for this population, highlighting the importance of studying 
medication adherence among young women. As medication becomes increasingly prevalent in 
our society and more and more young women are prescribed daily medication, understanding the 
factors that contribute to this important health behavior will become increasingly vital.  
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Table 1. Sample demographic characteristics 
Characteristic n or Mean % or SD 
Age (years) M: 19.38 SD: 2.44 
Race/Ethnicity  
     White/European American 
     Hispanic/Latina  
     Asian/Asian American  
     Black/African American 
     Native American 
     Something Else 
     Multiracial 
 
134 
25 
22 
16 
1 
4 
18 
 
73.2% 
13.7% 
12.0% 
8.7% 
0.5% 
2.2% 
9.8% 
Sexual Orientation 
     Straight/Heterosexual  
     Bisexual 
     Lesbian 
     Something Else 
     Don’t Know 
 
171 
9 
1 
1 
1 
 
93.4% 
4.9% 
0.5% 
0.5% 
0.5% 
Education Level 
     Freshman 
     Sophomore 
     Junior 
     Senior 
     Fifth Year 
 
72 
63 
37 
10 
1 
 
39.3% 
34.4% 
20.2% 
5.5% 
0.5% 
Living Situation 
     On Campus  
     Off Campus 
     At Home 
 
152 
16 
15 
 
83.1% 
8.7% 
8.2% 
Family Income 
     $10,000 or less 
     $10,001 to $20,000 
     $20,001 to $40,000 
     $40,001 to $60,000 
     $60,001 to $80,000 
     Over $80,000 
     Not Reported 
 
8 
8 
14 
21 
19 
110 
3 
 
4.4% 
4.4% 
7.8% 
11.7% 
10.6% 
61.1% 
1.6% 
Health Insurance Coverage 
     Private, through family 
     Private, through work 
     Private, through school 
     Public (e.g., Medicaid) 
     Not Reported 
 
 
 
119 
29 
6 
27 
2 
 
 
65.0% 
15.8% 
3.3% 
14.9% 
1.0% 
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Table 1 cont.   
Characteristic n or Mean % or SD 
Employment Status 
     Full Time 
     Part Time 
     Summer Job 
     Not Employed 
     Not Reported  
 
1 
73 
69 
39 
1 
 
0.5% 
39.9% 
37.7% 
21.3% 
0.5% 
 
 
 
Table 2. Participant Medication Usage 
 n or Mean % or SD 
# of Daily Medications  
     1 
     2 
     3 
     4 
     5 
     7 
M: 1.48 
119 
44 
12 
3 
1 
1 
SD: 0.85 
65.0% 
24.0% 
6.6% 
1.6% 
0.5% 
0.5% 
# of Total Medication Instructions M: 2.66 SD: 2.19 
Unpleasant Side Effects 24 14.2% 
Pts Taking Medication for:      
     Birth Control 
     Chronic Medical Condition 
     Mental Health Condition 
     ADD/ADHD 
     Sleep 
     Another Reason 
     Not Sure 
 
144 
27 
31 
12 
3 
10 
0 
 
78.7% 
14.8% 
16.9% 
6.6% 
1.6% 
5.5% 
0% 
 
 
Table 3. Medication Characteristics 
 N = 265 Medications 
n or Mean 
 
% or SD 
Means of Administration 
     By mouth, pill 
     By mouth, liquid 
     Inhaled 
     Topical/Onto Skin 
     Injected 
     Another Method 
 
249 
1 
7 
5 
2 
1 
 
94.0% 
0.4% 
2.6% 
1.9% 
0.8% 
0.4% 
# of Instructions per Medication M: 1.81 SD:1.14 
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Table 4. Summary of Risk Factor Variables 
 N = 180 
 Mean or n SD or % 
   
Beliefs About Medication 
     Specific-Concerns  
     Specific-Necessity 
     General-Overuse 
     General-Harm 
 
9.06 
10.87 
10.87 
7.95 
 
4.10 
5.57 
3.62 
2.60 
Perceived Barriers to Adherence 2.70 2.96 
Depressive Symptoms 
     CES-D >=16 
19.72 
n = 85  
12.13 
46.1% 
Perceived Stress 17.67 7.65 
Social Support 31.54 5.40 
Alcohol Use 
     AUDIT >=8 
6.13  
n = 45 
3.81 
24.6% 
Substance Use 
     DAST-10 >= 3 
0.60 
n = 9  
0.99 
4.9% 
Sleep Disturbance 
     DSM T-score > 60 
     Sleep Quality 
     Daytime Dysfunction 
20.19  
n =10 
2.11  
3.59  
5.24 
5.6% 
0.61 
1.29 
Global Executive Functioning 
     Behavior Regulation  
     Metacognition 
109.19 
47.77 
61.34 
27.24 
12.75 
16.22 
 
 
 
Table 5. MMAS-8 Results 
 N = 180 
n or Mean 
 
% or SD 
Problem with Adherence   
     Sometimes Forget 
     Missed in Last Two Weeks 
     Stopped Because Felt Worse  
     Stopped Because Felt Better  
     Forget to Bring 
     Missed Yesterday  
     Feel Hassled 
     Trouble Remembering 
 
133 
80 
34 
20 
109 
14 
41 
75 
 
72.7% 
43.7% 
18.6% 
10.9% 
59.6% 
7.7% 
22.4% 
40.9% 
Total MMAS-8 Score M: 3.30  SD: 1.71 
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Table 6. Associations between the adherence problems and medication-related variables 
 
Total # of 
Medications 
Total # of 
Instructions 
Concerns 
about Own 
Medications 
Perceived 
Necessity of 
Medications 
Beliefs about 
Medication 
Overuse 
Beliefs about 
Medication 
Harmfulness 
Total # of 
Barriers 
MMAS-8 Score        
   Pearson Correlation -0.045 -0.005 0.225** 0.038 0.014 0.060 0.453** 
   Significance (2-tail) n.s. n.s. 0.004 n.s. n.s. n.s. <0.001 
* p < 0.05, ** p < 0.01 
 
 
 
Table 7. Associations between the adherence problems and behavioral and psychosocial variables 
 Psychological 
Distress 
Social 
Support 
Alcohol 
Use 
Substance 
Use 
Sleep 
Disturbance 
Executive 
Dysfunction 
MMAS-8 Score       
   Pearson Correlation 0.263** -0.205* 0.167* 0.103 0.151* 0.317** 
   Significance (2-tail) 0.001 0.008 0.042 n.s. 0.047 <0.001 
* p < 0.05, ** p < 0.01 
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Table 8. Predicting Adherence (controlling for Hispanic/Latina ethnicity)  
 R2 p  p 
Beliefs About Medication 
     Specific-Concerns 
 
0.042 
 
0.001 
 
0.207 
 
0.007* 
Barriers to Adherence 0.160 < 0.001 0.401 < 0.001* 
Psychological Distress 0.061 <0.001 0.250 0.001* 
Social Support 0.037 0.005 -0.193 0.011* 
Alcohol Use 0.024 0.007 0.155  0.057 
Sleep Disturbance 0.018 0.020 0.135  0.073 
Global Executive Functioning 0.087 < 0.001 0.300 < 0.001* 
* significant after -correction 
 
 
 
Table 9. Hierarchical linear regression with all included risk factors  
R2 β p-value  ΔR2 𝜒2 for ΔR2 p-value  
Step 1  0.072 ----- ----- 0.072 7.664 0.007 
 
Hispanic/Latina  
 
0.268 0.007 
   
Step 2 0.333 ----- ----- 0.261 5.729 < 0.001 
 
Concerns  about 
Own Medications 
 
0.072 n.s. 
   
 Barriers to 
Adherence 
 0.416 <0.001    
 Psychological 
Distress 
 0.134 n.s.    
 Social Support  -0.059 n.s.    
 Alcohol Use   0.109 n.s.    
 Sleep 
Disturbance 
 -0.084 n.s.    
 Global Executive 
Functioning 
 0.269 0.024    
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Appendices 
 
Appendix A. Re-Coding of Participant-Reported Reason for their Medication 
Reported as “Another Reason” n Re-Coded Reason 
Acne/Skincare 15 Chronic Medical Condition 
Migraines/Headaches 3 Chronic Medical Condition 
Thyroid Condition/Hypothyroidism 3 Chronic Medical Condition 
Allergies 2 Chronic Medical Condition 
Polycystic Ovarian Syndrome 2 Chronic Medical Condition 
Immune support to compensate for a  
genetic condition 
2 Chronic Medical Condition 
Asthma 1 Chronic Medical Condition 
Anemia 1 Chronic Medical Condition 
Insulin Resistance 1 Chronic Medical Condition 
Anxiety 1 Mental Health Condition 
Anorexia Nervosa 1 Mental Health Condition 
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Appendix B. Matrix of Pearson’s correlation coefficients for medication-related and clinical variables  
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
1. MMAS-8 ---- -0.045 -0.005 0.225** 0.038 0.014 0.060 0.453** 0.263** -0.205** 0.167* 0.103 0.151* 0.317** 
2. # of 
Medications 
 ---- 0.656** 0.229** 0.503** -0.196* -0.117 0.138 0.223** -0.205** 0.007 0.087 0.161* 0.118 
3. # of 
Instructions 
  ---- 0.133 0.413** -0.076 -0.014 0.089 0.180* -0.121 0.017 0.017 0.100 0.020 
4. Concerns 
about Meds 
   ---- 0.591** 0.259** 0.361** 0.455** 0.473** -0.290** 0.124 0.114 0.352** 0.451** 
5. Perceived  
Necessity 
    ---- 0.083 0.007 0.356** 0.369** -0.276** -0.018 0.044 0.417** 0.298** 
6. Beliefs – 
Overuse 
     ---- 0.602** 0.121 0.172* 0.003 0.141 0.087 0.108 0.159 
7. Beliefs –  
Harmfulness 
      ---- 0.035 0.232** -0.261** 0.161 0.111 0.135 0.262** 
8. # of 
Barriers 
       ---- 0.370** -0.134 0.094 0.036 0.331** 0.446** 
9. Psych. 
Distress 
        ---- -0.518** 0.154 0.114 0.627** 0.652** 
10. Social 
Support 
         ---- 0.043 -0.107 -0.309** -0.435** 
11. Alc. Use           ---- 0.165* -0.068 0.193* 
12. Sub. Use            ---- -0.007 0.039 
13. Sleep 
Disturbance 
            ---- 0.510** 
14. Executive 
Dysfunction 
             ---- 
 
* p < 0.05, ** p < 0.05 
